Since most new drugs fail because of ADME/Tox, you can add considerable value to your compound by conducting early in vitro testing and preemptively demonstrating low risk data.

ADME/DMPK and Drug-Drug Interaction studies only cost a small fraction of the potential financial benefits that can be gained by providing this data. The data not only satisfies regulatory requirements and avoids the considerable expense of clinical failures, additional studies and approval delays, but also helps guide the development of the drug candidate and helps with ensuring patient safety.

View our infographic to learn about how you can leverage your data to showcase your compound in ways that will maximize its value.